BeCytes Biotechnologies

Executive Summary

BeCytes Biotechnologies is a Spanish biotech company specializing in high-quality primary liver cells (human and animal) and tissue sourcing for biomedical research, alongside preclinical CRO services. Founded in 2018 and based in the Barcelona Science Park, the company was acquired by BioIVT, a global leader in research models and services. This acquisition positions BeCytes to leverage BioIVT's extensive distribution network and client base, potentially accelerating its growth in the European and global markets. As a service-oriented entity, BeCytes does not develop proprietary therapeutics but provides essential tools and services for drug discovery and development, particularly in hepatotoxicity and liver disease research. The acquisition by BioIVT validates its technology and business model, offering stability and resources for expansion. However, its pre-clinical stage and dependence on external research funding and partnerships pose risks. Overall, BeCytes is well-positioned within the niche of primary liver cell products and CRO services, with a clear path to scaling under BioIVT's umbrella.

Upcoming Catalysts (preview)

• Q3 2026Integration with BioIVT's global distribution network leading to expanded market reach90% success
• Q4 2026Launch of new primary liver cell products for emerging research applications (e.g., NASH, fibrosis)70% success
• Q2 2026Major contract with pharmaceutical company for preclinical CRO services60% success